vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and eXp World Holdings, Inc. (EXPI). Click either name above to swap in a different company.

eXp World Holdings, Inc. is the larger business by last-quarter revenue ($1.2B vs $950.5M, roughly 1.3× Astrana Health, Inc.). Astrana Health, Inc. runs the higher net margin — 0.7% vs -1.1%, a 1.8% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 8.5%). eXp World Holdings, Inc. produced more free cash flow last quarter ($11.9M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 12.4%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

eXp World Holdings, Inc. is a global cloud-based real estate services provider. It operates the eXp Realty brokerage network, leverages immersive virtual 3D campus environments to support agent collaboration and operations, serves residential and commercial real estate markets across over 20 countries, and offers complementary services including mortgage, title insurance and professional development resources for real estate practitioners.

ASTH vs EXPI — Head-to-Head

Bigger by revenue
EXPI
EXPI
1.3× larger
EXPI
$1.2B
$950.5M
ASTH
Growing faster (revenue YoY)
ASTH
ASTH
+34.4% gap
ASTH
42.9%
8.5%
EXPI
Higher net margin
ASTH
ASTH
1.8% more per $
ASTH
0.7%
-1.1%
EXPI
More free cash flow
EXPI
EXPI
$17.9M more FCF
EXPI
$11.9M
$-6.0M
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
12.4%
EXPI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASTH
ASTH
EXPI
EXPI
Revenue
$950.5M
$1.2B
Net Profit
$6.6M
$-12.9M
Gross Margin
Operating Margin
1.9%
-1.1%
Net Margin
0.7%
-1.1%
Revenue YoY
42.9%
8.5%
Net Profit YoY
184.4%
-35.7%
EPS (diluted)
$0.12
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
EXPI
EXPI
Q4 25
$950.5M
$1.2B
Q3 25
$956.0M
$1.3B
Q2 25
$654.8M
$1.3B
Q1 25
$620.4M
$954.9M
Q4 24
$665.2M
$1.1B
Q3 24
$478.7M
$1.2B
Q2 24
$486.3M
$1.3B
Q1 24
$404.4M
$943.1M
Net Profit
ASTH
ASTH
EXPI
EXPI
Q4 25
$6.6M
$-12.9M
Q3 25
$373.0K
$3.5M
Q2 25
$9.4M
$-2.3M
Q1 25
$6.7M
$-11.0M
Q4 24
$-7.8M
$-9.5M
Q3 24
$16.1M
$-8.5M
Q2 24
$19.2M
$12.4M
Q1 24
$14.8M
$-15.6M
Gross Margin
ASTH
ASTH
EXPI
EXPI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
99.9%
Q2 24
99.9%
Q1 24
Operating Margin
ASTH
ASTH
EXPI
EXPI
Q4 25
1.9%
-1.1%
Q3 25
2.0%
0.3%
Q2 25
3.1%
-0.2%
Q1 25
3.3%
-1.1%
Q4 24
0.1%
-1.0%
Q3 24
5.9%
-0.7%
Q2 24
6.2%
1.4%
Q1 24
7.5%
-1.9%
Net Margin
ASTH
ASTH
EXPI
EXPI
Q4 25
0.7%
-1.1%
Q3 25
0.0%
0.3%
Q2 25
1.4%
-0.2%
Q1 25
1.1%
-1.2%
Q4 24
-1.2%
-0.9%
Q3 24
3.4%
-0.7%
Q2 24
3.9%
1.0%
Q1 24
3.7%
-1.7%
EPS (diluted)
ASTH
ASTH
EXPI
EXPI
Q4 25
$0.12
$-0.08
Q3 25
$0.01
$0.02
Q2 25
$0.19
$-0.01
Q1 25
$0.14
$-0.07
Q4 24
$-0.14
$-0.06
Q3 24
$0.33
$-0.06
Q2 24
$0.40
$0.08
Q1 24
$0.31
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
EXPI
EXPI
Cash + ST InvestmentsLiquidity on hand
$429.5M
$124.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$242.8M
Total Assets
$2.2B
$442.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
EXPI
EXPI
Q4 25
$429.5M
$124.2M
Q3 25
$463.4M
$112.8M
Q2 25
$342.1M
$94.6M
Q1 25
$260.9M
$115.7M
Q4 24
$290.8M
$113.6M
Q3 24
$350.3M
$130.4M
Q2 24
$327.7M
$108.4M
Q1 24
$337.3M
$109.2M
Stockholders' Equity
ASTH
ASTH
EXPI
EXPI
Q4 25
$779.3M
$242.8M
Q3 25
$775.5M
$235.3M
Q2 25
$765.5M
$218.4M
Q1 25
$745.4M
$212.0M
Q4 24
$712.7M
$204.9M
Q3 24
$704.6M
$211.1M
Q2 24
$678.9M
$220.3M
Q1 24
$653.5M
$222.4M
Total Assets
ASTH
ASTH
EXPI
EXPI
Q4 25
$2.2B
$442.5M
Q3 25
$2.2B
$458.7M
Q2 25
$1.4B
$481.2M
Q1 25
$1.3B
$435.8M
Q4 24
$1.4B
$390.7M
Q3 24
$1.3B
$432.6M
Q2 24
$1.3B
$457.4M
Q1 24
$1.2B
$426.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
EXPI
EXPI
Operating Cash FlowLast quarter
$-2.9M
$13.8M
Free Cash FlowOCF − Capex
$-6.0M
$11.9M
FCF MarginFCF / Revenue
-0.6%
1.0%
Capex IntensityCapex / Revenue
0.3%
0.2%
Cash ConversionOCF / Net Profit
-0.44×
TTM Free Cash FlowTrailing 4 quarters
$104.5M
$109.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
EXPI
EXPI
Q4 25
$-2.9M
$13.8M
Q3 25
$10.0M
$28.9M
Q2 25
$90.9M
$36.1M
Q1 25
$16.6M
$39.8M
Q4 24
$-10.9M
$13.7M
Q3 24
$34.0M
$46.0M
Q2 24
$23.2M
$71.1M
Q1 24
$6.0M
$60.7M
Free Cash Flow
ASTH
ASTH
EXPI
EXPI
Q4 25
$-6.0M
$11.9M
Q3 25
$7.4M
$26.6M
Q2 25
$89.5M
$33.3M
Q1 25
$13.6M
$37.3M
Q4 24
$-13.5M
$11.6M
Q3 24
$31.7M
$44.4M
Q2 24
$20.4M
$69.7M
Q1 24
$5.6M
$59.3M
FCF Margin
ASTH
ASTH
EXPI
EXPI
Q4 25
-0.6%
1.0%
Q3 25
0.8%
2.0%
Q2 25
13.7%
2.5%
Q1 25
2.2%
3.9%
Q4 24
-2.0%
1.1%
Q3 24
6.6%
3.6%
Q2 24
4.2%
5.4%
Q1 24
1.4%
6.3%
Capex Intensity
ASTH
ASTH
EXPI
EXPI
Q4 25
0.3%
0.2%
Q3 25
0.3%
0.2%
Q2 25
0.2%
0.2%
Q1 25
0.5%
0.3%
Q4 24
0.4%
0.2%
Q3 24
0.5%
0.1%
Q2 24
0.6%
0.1%
Q1 24
0.1%
0.1%
Cash Conversion
ASTH
ASTH
EXPI
EXPI
Q4 25
-0.44×
Q3 25
26.69×
8.26×
Q2 25
9.65×
Q1 25
2.48×
Q4 24
Q3 24
2.11×
Q2 24
1.21×
5.75×
Q1 24
0.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

EXPI
EXPI

North American Realty$1.1B96%
International Realty$42.2M4%

Related Comparisons